Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

Also called NCT06866236

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Ebima Clifford Okundaye (from the registry)
Registry
  • NCT NCT06866236
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06866236. Randomized; single masking; primary purpose treatment. Start 2025-10 (anticipated); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Acronym
NAD agent
Condition
Chronic Kidney Diseases
Condition
Kidney Failure
Intervention (Drug)
QRX-3
Lead sponsor
Ebima Clifford Okundaye (class: industry)

Record details

Record id
cardio:ct-nct06866236
Content hash
f53dd2994a4a40b1cb5431b5549a87008f89063421b7b0acf7aa2163135645ad